Pure Global

BHV-7000 Acute Treatment of Bipolar Mania - Trial NCT06419582

Access comprehensive clinical trial information for NCT06419582 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Biohaven Therapeutics Ltd. and is currently Not yet recruiting. The study focuses on Bipolar Disorder. Target enrollment is 256 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06419582
Phase 2/3
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06419582
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
BHV-7000 Acute Treatment of Bipolar Mania
A Phase 2/3, Multicenter, Inpatient, Placebo-Controlled, Double-blind Trial of BHV-7000 for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder

Study Focus

Bipolar Disorder

BHV-7000

Interventional

drug

Sponsor & Location

Biohaven Therapeutics Ltd.

Biohaven Pharmaceuticals, Inc.

Timeline & Enrollment

Phase 2/3

Jun 01, 2024

Apr 01, 2025

256 participants

Primary Outcome

Change in Young Mania Rating Scale (YMRS) total score from baseline to day 21

Summary

The purpose of this study is to determine whether BHV-7000 is a safe and effective acute
 treatment for manic episodes in bipolar disorder I.

ICD-10 Classifications

Bipolar affective disorder
Bipolar affective disorder, unspecified
Other bipolar affective disorders
Bipolar affective disorder, currently in remission
Bipolar affective disorder, current episode mixed

Data Source

ClinicalTrials.gov

NCT06419582

Non-Device Trial